Search Results for: GNPX

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced its placement in an editorial published by NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company for private and public entities. The publication, titled “Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers,” may be accessed via the following link: http://ibn.fm/FQ6yC. The editorial reads,“‘Disruptive’ isn’t … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Highlighted in Editorial on Potential Breast Cancer Treatments”

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that it will present, via webcast, at the Singular Research Midwestern Values Conference on September 19, 2019. Genprex Chairman and CEO Rodney Varner will lead the company’s webcast presentation. The presentation is scheduled to begin at 4:00 PM Central Time, and interested parties may register … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) CEO to Present Via Webcast at September 19 Singular Research Midwestern Values Conference”

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that non-affiliated, independent researchers have reported in a recent study that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex(TM) immunogene therapy, prevented tumor growth in triple-negative breast cancer (“TNBC”). Currently considered an incurable cancer, there are limited therapeutic options available for … Continue reading “QualityStocksNewsBreaks – Genprex, Inc.’s (NASDAQ: GNPX) TUSC2 Found to Prevent Tumor Growth in Triple-Negative Breast Cancer by Independent Researchers”

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) on Tuesday issued an update regarding its clinical development programs, manufacturing and strategy for bringing its Oncoprex(TM) immunogene therapy to market. A corporate presentation is available on GNPX’s website which details anticipated milestones and future guidance for the company. “These milestones emphasize our commitment to developing potentially life-changing … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Issues Corporate Update; Set to Present at H.C. Wainwright 21st Annual Global Investment Conference”

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that its Chairman and Chief Executive Officer, Rodney Varner, is scheduled to present at the 4th Annual Disruptive Growth Conference. ReedSmith is hosting the event, which features growth companies with disruptive technologies and business models across a variety of sectors, at its offices at 599 … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Chairman and CEO to Present at the 4th Annual Disruptive Growth Conference”

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced its recent achievements as part of the company’s overall strategy to expand its clinical development programs and bring its lead drug candidate, Oncoprex(TM) immunogene therapy, to commercialization. Per the update, Genprex has published recent as well as historical achievements to its newly launched, interactive corporate … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Recent Achievements as Part of Overall Expansion Strategy”

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that its manufacturing partner, Aldevron, has successfully completed the manufacturing of the TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA per the manufacturing agreement between the companies that was disclosed in September 2018. According to the update, Genprex’s Oncoprex(TM), the company’s initial product candidate, consists of … Continue reading “QualityStocksNewsBreaks – Genprex, Inc.’s (NASDAQ: GNPX) Manufacturing Partner Aldevron Completes Significant Manufacturing Step for Initial Product Candidate, Oncoprex(TM)”

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced it has initiated the first phase of branding its lead drug candidate, Oncoprex(TM) immunogene therapy, and has completed and submitted non-proprietary drug name selections to the American Medical Association’s United States Adopted Names (“USAN”) Council. According to the update, Genprex will, upon receipt of USAN … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Initiates First Phase of Branding Lead Drug Candidate”

Clinical-stage gene therapy company Genprex Inc. (NASDAQ: GNPX) this morning provided an update on the development of its lead drug candidate, Oncoprex(TM) immunogene therapy, in combination with immunotherapy for the treatment of non-small cell lung cancer (“NSCLC”). Based on data from the ongoing study through GNPX’s July 2018 sponsored research agreement with The University of … Continue reading “QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Provides Update on Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer”